Bio-Thera Solutions is a global biopharmaceutical company focused on the development of innovative antibody drugs aimed at treating serious diseases such as cancer, autoimmune disorders, and cardiovascular diseases. The company has successfully launched several products, including the first domestically produced adalimumab injection, known as 格乐立® (Geleli), along with other therapeutic agents like 普贝希® (Pubeixi), 施瑞立® (Shirili), and 贝塔宁® (Beitaning). These products reflect Bio-Thera's commitment to addressing urgent clinical needs through scientific innovation.

The company has established a robust research and development platform that adheres to stringent quality management systems compliant with Good Manufacturing Practice (GMP) standards in the United States, Europe, and China. This commitment to quality ensures that their products meet high safety and efficacy standards. Bio-Thera Solutions continues to explore new therapeutic avenues and expand its product pipeline, reinforcing its mission of "innovation only for life" to meet the pressing healthcare challenges faced by patients globally.

China

Bio-Thera Solutions is a clinical-stage pharmaceutical company focused on biologic therapeutics. Bio-Thera is developing a pipeline on innovative enhanced monoclonal antibodies and antibody-drug conjugates for the treatment of a broad range of cancers and other diseases as well as a pipeline of biosimilars in the autoimmune and oncology therapeutic areas. The company is headquartered in Guangzhou, China.

Bio-Thera Solutions

Company Details